Skip to main content

Advertisement

SpringerLink
Log in

CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Objective: The present study evaluated the feasibility of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy in patients with peripheral T cell lymphomas (PTCLs). Patients and methods: Twenty-six patients with newly diagnosed PTCLs were enrolled into the pilot study. Treatment consisted of classical CHOP plus etoposide 100 mg/m2 intravenously (i.v.) on day 1 and gemcitabine 600 mg/m2 i.v. on day 1 in a 3 week interval. Results: Fifteen complete responses (CR, 57.7%) or one unconfirmed complete response (uCR, 3.8%) and four partial responses (PR, 15.4%) were confirmed, giving an overall response rate of 76.9% (95% CI, 58.3–96.3%). Median survival has not yet been reached, while median event free survival was 215 days at a median follow-up duration of 383 days. Estimated overall survival at 1 year was 69.6%. The most severe haematological adverse event was neutropaenia, which occurred with a grade 4 intensity in 14 patients (53.8%). Additionally, febrile neutropaenia was observed in four patients (15.4%). However, there was no treatment-related death. Conclusion: The CHOP-EG regimen was found to be feasible in patients with PTCLs. For further investigation on the role of gemcitabine in the treatment of PTCLs, a more large scale phase II or phase III study is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gordon LI, Harrington D, Anderson J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A (1992) Comparison of a second generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med 327:1342–1349

    PubMed  CAS  Google Scholar 

  2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    Article  PubMed  CAS  Google Scholar 

  3. Lee CH, Im YH, Ryoo BY, Nam SM, Kim MS, Lee YS, Oh KK, Shim YS, Yoo SY, Lee JO, Kang TW, Kang YK (1998) Primary CHOP chemotherapy followed by involved field radiation therapy in clinical stage I or II aggressive non-Hodgkin’s lymphomas. Cancer Res Treat 30:809–817

    Google Scholar 

  4. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International lymphoma study group. Blood 84:1361–1392

    PubMed  CAS  Google Scholar 

  5. Melnyk A, Rodrguez A, Pugh WC, Cabannillas F (1997). Evaluation of the revised European–American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin’s lymphoma. Blood 89:4514–4520

    PubMed  CAS  Google Scholar 

  6. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825–2833

    PubMed  CAS  Google Scholar 

  7. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23:4117–4126

    Article  PubMed  CAS  Google Scholar 

  8. Koppler H, Pfluger KH, Eschenbach I, Pfab R, Lennert K, Wellens W, Schmidt M, Gassel WD, Kolb T, Hassler R (1989) CHOP-VP16 chemotherapy and involved field irradiation for high grade non-Hodgkin’s lymphoma: a phase II multicenter study. Br J cancer 60:79–82

    PubMed  CAS  Google Scholar 

  9. Karakas T, Bergmann L, Stutte HJ, Jager E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D (1996) Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas. Leuk lymphoma 24:121–129

    Article  PubMed  CAS  Google Scholar 

  10. Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, Paul N, Shepherd L, Iglesias J, Meyer R (2004) Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin’s lymphoma. Cancer 101:1835–1842

    Article  PubMed  CAS  Google Scholar 

  11. Sallah S, Wan JY, Nguyen NP (2001) Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113:185–187

    Article  PubMed  CAS  Google Scholar 

  12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphoma. J Clin Oncol 17:1244–1253

    PubMed  CAS  Google Scholar 

  13. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazals-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J (1998) Prognostic singnificance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Blood 92:76–82

    PubMed  CAS  Google Scholar 

  14. Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, Park CH, Ko YH, Ree HJ, Park K (2002) Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European–American lymphoma (REAL) classification. Eur J Cancer 38:75–81

    Article  PubMed  CAS  Google Scholar 

  15. Pfreudnschuh M, Trumper L, Kloess M, Schmits r, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626–633

    Article  Google Scholar 

  16. Zinzani PL, Magagnoli M, Bendandi M, Orcioni GF, Gherlinzoni f, Albertini P (1998) Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol 9:1351–1353

    Article  PubMed  CAS  Google Scholar 

  17. Plunkett W, Huang P, Searcy CE, Gandhi V (1996) Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 23:3–15

    PubMed  CAS  Google Scholar 

  18. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2’,2’-difluorodeoxycytidine and 1-beta-D-arabinofuranosyl-cytosine. Cancer Res 48:4024–4031

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, Kyungpook National University Hospital, 50 Samduck 2-Ga, Jung-Gu, Daegu, 700-721, South Korea

    Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Dong Hwan Kim, Jin Ho Baek & Kyu Bo Lee

  2. Department of Hematology/Oncology, Chonnam National University Hospital, Gwangju, South Korea

    Je-Jung Lee, Ik-Joo Chung, Hyeoung-Joon Kim & Deok-Hwan Yang

  3. Department of Hematology/Oncology, Inje University Hospital, Busan, South Korea

    Won-Sik Lee, Young-Don Joo & Chang-Hak Sohn

Authors
  1. Jong Gwang Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang Kyun Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yee Soo Chae
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dong Hwan Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jin Ho Baek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kyu Bo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Je-Jung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ik-Joo Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hyeoung-Joon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Deok-Hwan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Won-Sik Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Young-Don Joo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Chang-Hak Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sang Kyun Sohn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J.G., Sohn, S.K., Chae, Y.S. et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58, 35–39 (2006). https://doi.org/10.1007/s00280-005-0136-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0136-y

Keywords

Search

Navigation